Drug Trial Radar · NCT03743376
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
Last checked: Nov 19, 2026Latest source record: May 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Dec 12, 2018
Primary completion
Oct 15, 2020
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- United BioPharmaIndustry
- Sponsor type
- Industry
- Collaborators
- National Taiwan University Hospital; Taipei Veterans General Hospital, Taiwan; Taoyuan General Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Veterans General Hospital.
- First posted
- Nov 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients
Conditions
- HIV-1 Infection
Interventions
UB-421(25 mg/kg) Q2WBiological
Monoclonal antibody by IV infusion plus standard ART
UB-421(25 mg/kg) Q4WBiological
Monoclonal antibody by IV infusion plus standard ART
Primary outcomes
What the sponsor says the trial is designed to measure.
- treatment related TEAEsTime frame: 48Weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.